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Abstract
Human immunodeficiency virus type 1 (HIV-1) infection confers an increased risk for
the development of many cancers. Although the incidences of acquired immunodefi-
ciency syndrome (AIDS)-defining malignancies have declined since the advent of anti-
retroviral therapy (ART), a number of non-AIDS–defining cancers appear more
common in HIV-1–infected individuals relative to the general population. ART-treated
HIV-1–infected subjects are also aging, leading to an increased cancer burden in these
populations. However, longevity alone is not sufficient to explain these epidemiologic
trends. A causative link between HIV-1–induced immune suppression and elevated
cancer risk is well defined in certain malignancies; however, the direct role of HIV-1
replication products in oncogenesis remains unclear. Nevertheless, it is evident that
cooperation between HIV-1 and co-infecting viruses in targeting immune compartments
as well as nonimmune microenvironments can regulate both the development and
progression of cancer. Treating cancer in HIV-1–infected patients remains challenging
due to drug interactions, compounded side effects and intensified immunosuppression
from chemotherapy and/or radiation. While survival of HIV-1–infected patients with
certain cancers now rivals that of their uninfected counterparts, a better understanding
of HIV-1–induced oncogenesis, viral mechanisms of immune perturbation, nonimmune
microenvironmental abnormalities and outcomes of therapy will provide the basis for
better diagnosis and management of cancer.
Keywords: HIV-1, cancer, non-AIDS–defining cancer, AIDS-defining cancer, coinfection
1. Introduction
The acquired immune deficiency syndrome (AIDS) caused by chronic infection with the
human immunodeficiency virus type 1 (HIV-1) leads to severe immunosuppression and death
from immunologic and neurologic dysfunction as well as a number of opportunistic infections
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if left untreated. Prior to the introduction of anti-retroviral therapy (ART), the risk of AIDS
patients developing Kaposi’s sarcoma (KS), non-Hodgkin’s lymphoma (NHL) and cervical
cancer was enhanced by several fold. These three cancers have been referred to as AIDS-
defining cancers (ADCs). Since 1996, when ART became readily available, the incidence of
ADCs dramatically decreased and this was attributed to the partial restoration of immune
function [1]. With the HIV-1–infected patient population now living longer, however, these
individuals exhibit an increased risk of developing other types of cancers that are referred to as
non-AIDS–defining cancers (NADCs) [2]. NADCs can be classified as either virus or nonvirus
related. Although many of these cancers are directly linked to HIV-1 infection, many are not.
Several factors have been associated with the elevated number of cases of NADCs observed in
the last couple of decades, including low CD4+ T-cell counts, chronic inflammation, tobacco
usage, alcohol exposure, long-term ART exposure, advanced age and co-infection with onco-
genic viruses. Some of the viruses associated with the development of NADCs include human
papillomavirus (HPV), Epstein-Barr virus (EBV), human T-cell leukemia virus type 1 (HTLV-
1), hepatitis B virus (HBV) and hepatitis C virus (HCV).
Several lines of evidence have established an association between chronic HIV-1 infection and
the development of cancer. In this review, we examine the epidemiology, etiology and patho-
logical characteristics of cancer in the setting of chronic HIV-1 infection. We also discuss the
direct participation of HIV-1 proteins such as the transactivator of transcription (Tat) protein
and the envelope glycoprotein (gp)120 in potentiating tumorigenesis as well as cooperation
between HIV-1 and co-infecting viruses in inducing cell transformation. In addition, we dis-
cuss the interactions between HIV-1 and immune as well as nonimmune microenvironments
and their involvement in driving oncogenesis and cancer progression. Finally, challenges to the
management of cancer in HIV-1–infected patients will be investigated, with a focus on the
development of evidence-based treatment approaches that combine ARTwith effective cancer
treatment plans.
2. Types of cancers observed in HIV-1–infected patients
The success of ART has extended the life span of many HIV-1–infected patients; however, with
an improved life span comes an increased risk of developing a number of chronic conditions
and malignancies such as cardiovascular disease, neurologic syndromes and cancer [3]. The
latter accounts for approximately 25–35% of HIV-1–associated deaths, with lymphoma being
the most common cause of cancer among HIV-1–infected individuals [4]. As previously indi-
cated, the cancers that affect these individuals have been generally divided into two main
categories: ADCs and NADCs.
2.1. AIDS-defining cancers (non-Hodgkin’s lymphoma, Kaposi’s sarcoma and cervical
cancer)
2.1.1. Non-Hodgkin’s lymphoma (NHL)
The Center for Disease Control and Prevention (CDC) classified non-Hodgkin’s lymphoma
(NHL), Kaposi’s sarcoma (KS) and cervical cancer as ADCs. The occurrence of any of these
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cancers in HIV-1–infected individuals indicates the progression of HIV-1 infection to AIDS [5].
After the introduction of the ART in 1996, a dramatic improvement in immunologic function in
HIV-1–infected subjects was observed as well as a rapid decline in the number of AIDS-related
deaths [3].
NHL originates from malignant transformation of the precursor and mature forms of B, T and
natural killer (NK) cells that mainly migrate to the lymphoid organs and the hematopoietic
tissues but also to other organs [6]. There are 35 types of NHL, which can be differentiated
based on histology. The CDC initially classified four of these as ADCs, which include diffuse
large B cell lymphoma (DLBCL) with centroblastic characteristics, DLBCL with immunoblastic
features, primary nervous system lymphoma (PNSL) and Burkitt’s lymphoma [1]. In the
setting of HIV-1 infection, EBV has been linked to the etiology of NHL [7]. Even though the
number of cases of NHL associated with HIV-1 infection initially declined following the
introduction of ART, the incidence of NHL in the HIV-1–infected population remains elevated
and is 4–23 times higher than uninfected individuals [8]. A study conducted by Achenbach
et al. demonstrated that the incidence of NHL remains high even in HIV-1–infected patients on
ART. For instance, the incidence of NHL in HIV-1–infected individuals with HIV-1 viral loads
of 51–500 RNA copies/ml and those individuals with CD4+ T-cell counts >200 cells/μl remains
elevated. By the year 2000, NHL accounted for 11% of deaths among HIV-1–infected individ-
uals and that number had only decreased by 1% five years later [8].
A study conducted by Gopal et al. established the mortality and predictive indicators of death in
a cohort of 23,050 HIV-1–infected patients from 1996 to 2010. Of the total patients enrolled in this
study, 476 patients developed lymphoma, of which 79 patients were diagnosed with Hodgkin’s
lymphoma (HL), 201 patients with DLBCL, 54 patients with PNSL and the remaining 86 patients
were diagnosed with other types of NHL. Furthermore, in 223 patients, lymphoma appeared
despite ART. The 5-year survival rate was 50% for patients with BL, 44.1% for those with DLBCL,
22.8% for those with primary brain lymphoma and 43.3% of patients with other types of NHL.
The overall identification of risk factors for mortality included increased age, lymphoma diagno-
sis while on ART, a low CD4+ T-cell count and high viral load [4].
Another study in which results from a number of AIDS registries was linked to several cancer
registries demonstrated that there were differences in the clinical presentation of NHL pre- and
post-ART. In the pre-ART era (1983–1995), 33% and 38% of patients were presented with intermedi-
ate- and high-grade systemic NHL, respectively. Following the introduction of ART, the percentage
of patients with intermediate-grade NHL increased to 49%, whereas the percentage of patients with
high-grade NHL decreased to 19% [9]. Additionally, the survival rate of patients with systemic NHL
increased significantly in the post-ART era relative to the pre-ART era, with a rise from 4 months as
seen pre-ART to 9 months post-ART. There was also a change in the proportion of patients who had
NHL of CNS origin, with a decrease from 28% pre-ART to 17% post-ART. However, this decrease in
incidence did not correlate with an increase in survival rate [9].
2.1.2. Kaposi’s sarcoma (KS)
KS is a neoplasm that arises from mesenchymal cells at multiple foci and involves the recruit-
ment of inflammatory cells, malignant transformation of endothelial cells and neoangiogenesis
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[10]. In the context of HIV-1 infection, KS development is linked to co-infection with human
herpes virus 8 (HHV-8). The formation of KS lesions is associated with immunosuppression,
reactivation of a latent HHV-8 infection and activation of the immune response [11]. Before the
onset of the AIDS pandemic, KS was a very rare cancer. In the United States, the incidence of
KS between 1973 and 1978 within the white male population was 0.3 per 100,000 person-years.
This trend dramatically increased with the onset of the AIDS epidemic, peaking by 1985–1986.
It has been estimated that by 1989–1991, the occurrence of KS was 8.9 per 100,000 person-years
[1]. Between 1990 and 1995, KS was the most prevalent AIDS-defining cancer in the United
States. During this time, HIV-1–infected individuals were at a 53,000 fold-increased risk of
developing KS compared to the general population [1]. Following the introduction of ART,
however, the incidence of KS decreased considerably due to three factors: (i) decreased HIV-1
replication; (ii) improvement in the HHV-8-specific immune response; and (iii) the angiogene-
sis inhibitory effects associated with protease inhibitors used to treat HIV-1 infection [12].
Accordingly, the immune status of patients plays a large role in the development of KS. In fact,
patients who developed KS while on ART began with low CD4 counts and usually developed
KS within 6 months of beginning therapy [13]. Other studies have also shown that while ART
did decrease the risk of KS, those who proceeded to develop KS while on ART exhibited
evidence of virologic failure [14]. These collective observations underscore the important link
between decreased immune function due to HIV-1 infection and the development of KS.
2.1.3. Cervical cancer
Cervical cancer is a neoplastic condition that originates in the cervix. In 1993, invasive cervical
cancer began to be included as an AIDS-defining diagnosis. Epidemiological evidence sug-
gests that the precursor lesions, cervical intraepithelial neoplasia, or squamous intraepithelial
lesion occur more frequently in women with HIV-1 [15]. In HIV-1–infected females, co-infec-
tion with the HPV is associated with invasive cervical cancer. Notably, it is estimated that HPV
accounts for 70% of all cervical cancer cases [16]. However, not all women living with HPV
infection develop cervical cancer. Factors that may influence the development of cervical
cancer include a high level of HPV DNA, sustained HPV infection and infection with certain
“high-risk” subtypes of HPV, including HPV 16 and 18. In the context of co-infection with HIV-
1, a reduced CD4+ T-cell count is associated with an elevated risk of developing cervical cancer
[17]. Furthermore, cervical cancer presents in a more aggressive form with a lower survival
time in HIV-1–infected women compared to women who are not infected with HIV-1. Even
though ART leads to partial restoration of immune function in HIV-1–infected patients, it
remains uncertain whether the incidence of cervical cancer among HIV-1–infected women has
been affected by ART.
Studies of patient cohorts in which individual subject data concerning ART use were exam-
ined have generated conflicting results, with reduced risk attributed to this therapy reported
in some but not in all cases [18]. In contrast, other groups have documented an increased risk
for developing invasive cervical cancer following the introduction of ART (e.g., relative risk:
1.46 with a 95% confidence interval of 1.09–1.94) [19, 20]. These discordant results could have
several explanations including the increased life expectancy of HIV-1–infected female
patients and/or inadequate screening programs for these women [21]. Nevertheless, it is
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evident that ART may not prevent the appearance of invasive cervical cancer as it was
previously thought. A more recent study which focused on assessing prevalence and identi-
fying associated risk factors for developing precancerous cervical lesions among HIV-1–
infected women in Kenya demonstrated that subjects who were not treated with ART were
2.21 times more likely to present with precancerous lesions than ART patients [22]. Although
the mechanisms underlying how ART-mediated immune reconstitution affects HPV-induced
lesions are unclear, the regular screening of HIV-1–infected women remains critically impor-
tant. In this regard, the initiation of ART could act as leverage for cancer screening in
resource-limited settings [22].
2.2. Non-AIDS-defining cancers: Virus related (EBV, HPV, HBV, HCV, and HTLV-1)
With the improvement in morbidity, mortality and life expectancy linked to the introduction of
ART, the incidence of ADCs has declined, whereas the incidence of NADCs has paradoxically
increased. Examples of NADCs include lung cancer, hepatocellular carcinoma (HCC), colorec-
tal cancer, anal cancer and Hodgkin’s lymphoma (HL) among others [3]. While ADCs have
been demonstrated to potentially be associated with viral co-infection (i.e., KS linked to infec-
tion with HHV-8), NADCs can also be further categorized as either virus or nonvirus related.
Unfortunately, HIV-1–infected patients have an increased risk of exposure and subsequent
infection with oncogenic viruses, including hepatitis B and C virus (HBV and HCV), human
papillomavirus (HPV), Epstein-Barr virus (EBV) and human T-cell leukemia virus type 1
(HTLV-1). This elevated risk of exposure lies on a continuum with the development of cancer
as a direct result of infections with these tumorigenic viruses, even in the post-ART era [23].
2.2.1. Epstein-Barr virus (EBV): Hodgkin’s lymphoma (HL)
In individuals not infected with HIV-1, between 20% and 50% of HL cases have been
attributed to EBV infection; however, 75–100% of the HL cases observed in HIV-1–infected
patients have been etiologically attributed to EBV infection. It has been postulated that
aberrant CD4+ T-cell responses specific to EBV in HIV-1–infected patients are risk factors
for developing HL [24]. After the introduction of ART, lymphoma became the major cause
of cancer-related death in the HIV-1–infected patient population. It was reported in a study
of 23,050 HIV-1–infected patients enrolled between 1996 and 2010 that 476 (2.1%) individ-
uals were diagnosed with lymphoma, of which 79 patients (16.6%) developed HL. At the
time of diagnosis, the mean age was 42.1 years with a mortality rate for HL reported at
7.9% and a 5-year survival of 61.6% [4].
The incidence of HL may be increasing since the advent of ART [25–32], which is likely due to
the improvement in the level of immune function [33]. However, the increased relative risk of
HL is lower than that observed for aggressive B-cell lymphoma [33]. Prior to the advent of
ART, the prognosis of HIV-1–associated HL was poor, with very few individuals cured of their
disease [34]. In accordance with these observations, the importance of ART has been demon-
strated in the context of improving responses to chemotherapy and prolonging overall sur-
vival [35, 36]. Furthermore, HIV-1–infected patients with HL who do not respond to ART have
poor outcomes resembling those of the pre-ART era [36]. Additional retrospective and
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prospective clinical results strongly imply that HIV-1–infected patients with HL who are
treated with full-dose chemotherapy and concurrent cART have a significantly improved and
comparable prognosis as the uninfected population [37, 38]; gradual recovery of immune
function occurs over the course of 6–9 months from the completion of treatment [37, 39].
2.2.2. Chronic viral hepatitis (HBV and HCV): Hepatocellular carcinoma (HCC)
It is estimated that 480–540 million people worldwide are currently affected by chronic viral
hepatitis. Of these individuals, 350–370 million are infected with HBV and 130–170 million
with HCV [40]. In the United States, approximately 25% and 10% of HIV-1–infected persons
are co-infected with HCV and HBV, respectively. HCC, a malignancy that arises from hepato-
cytes, is the fifth leading cause of cancer-related deaths worldwide. An excess of alcohol
consumption and viral hepatitis caused by infection with HBVor HCVare the main etiological
factors of HCC [41]. In chronic HIV-1 infection, the development of HCC is mainly associated
with co-infection with HBV and HCV [42]. Furthermore, liver diseases account for 50% of the
mortality in the HIV-1–infected patient population, representing one of the three major causes
of non-AIDS–associated deaths [41, 43], with HCC remaining the second leading cause of
death in these people [42].
HIV-1 infection increases the risk of developing HCC by seven fold [44]. Indeed, HIV-1 co-
infection with HBV or HCV accelerates the progression of either of these infections to liver
cirrhosis and ultimately the induction of HCC [42]. In addition to other complications stem-
ming from co-infection, ART has been linked to hepatotoxicity, the effects of which are exacer-
bated in patients chronically co-infected with HBV or HCV [42]. Additionally, a recent study
demonstrated significant differences in the course of HCC progression between HIV-1–
infected individuals co-infected with HBV and/or HCV compared to non-HIV-1 co-infected
subjects. For instance, HIV-1–infected individuals were diagnosed with HCC at a younger age
relative to HIV-1 seronegative subjects (48.03±7.4 versus 67.54±9.6). Even though the rate of
HCC reappearance following treatment was similar in both groups, HIV-1–infected patients
were re-treated more times and had shorter overall survival rates than in the absence of HIV-1
infection [45].
2.2.3. Human papilloma virus (HPV): anal cancer
Anal cancer rarely occurs in the general population. In contrast, the incidence of anal cancer
has been increasing since the introduction of ART in HIV-1–infected patients [3]. The risk of
developing anal cancer among HIV-1–infected people is 33- to 222-fold higher compared to
their uninfected counterparts [46]. Anal cancer particularly affects men who have sex with men
between the ages 45–50 [3]. In addition, there have been reports of HIV-1–infected women with
abnormal anal cytology, accompanied by the presence of high-risk HPV types [47, 48]. Squa-
mous cell carcinoma (SCC), which originates from the anal canal, is the most prevalent type of
anal cancer and its incidence has increased 96% in men and 39% in women over recent decades
[3, 46].
Although not all anal cancers are associated with HPV infection, co-infection with HPV 16 is
linked to the pathogenesis of SCC. The prevalence of anal HPV 16 co-infection is three to
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fivefold higher in HIV-1–infected individuals compared to individuals without HIV-1 infec-
tion. Low levels of CD4+ T cells correlate with the persistence of HPV infection and predispose
individuals to the formation of premalignant anal lesions. Notably, HIV-1–infected females
with a history of cervical disease are at an increased risk for developing high-grade anal
intraepithelial neoplasia [48–50]. Progression of these lesions into invasive anal cancer occurs
as the life span of HIV-1–infected patient populations has been extended due to ART [3].
Screening and treatment protocols are not yet well established for these types of malignancies,
which underscore the need for research on anal HPV-associated disease, particularly in the
setting of HIV-1 infection.
2.2.4. Human T-cell leukemia virus (HTLV-1): adult T-cell leukemia/lymphoma (ATL and ATLL)
Leukemia is a hematologic cancer characterized by the expansion of immature or abnormal
leukocytes [51]. HTLV-1 infects CD4+ T cells, which leads to a malignancy that affects 20
million people worldwide. In less than 5% of the infected patients, HTLV-1 infection can cause
adult T-cell leukemia (ATL) or adult T-cell leukemia/lymphoma (ALL) [52]. In the context of
HIV-1 infection, co-infection with HTLV-1 is linked to the etiology of leukemia and lymphoma
[51]. HIV-1/HTLV-1 co-infection is frequently encountered in areas where HTLV-1 infection is
more prevalent, particularly among high risk groups such as intravenous drug users. In areas
where HIV-1 infection is high, 10% of HIV-1–infected patients are also co-infected with HTLV-1
[52]. The worldwide incidence of leukemia/lymphoma in individuals co-infected with HIV-1
and HTLV-1 is currently unclear [52]. In a cohort of 21,000 patients residing in the United
States, Poiesz et al. studied the prevalence of HTLV-1–induced T-cell lymphoma and found
eight patients with lymphoma who tested positive for HTLV-1. One of these patients was also
co-infected with HIV-1, presenting with a stage IV lymphoma [53]. In a case study of a 43-year-
old African American male with ATL and HIV-1/HTLV-1 co-infection, it was reported that a
period of remission after treatment with chemotherapeutic agents and zidovudine was
achieved demonstrating, at least in this patient, that co-infection with HIV-1 may not prevent
effective cancer treatment [52].
2.3. Non-AIDS-defining cancers: Nonvirus related (lung cancer, colorectal cancer, and
prostate cancer)
2.3.1. Lung cancer
Malignant transformation of lung cells results in the development of lung cancer. Lung
cancer is responsible for the majority of cancer-related deaths in men and women in the
United States. In 2013, approximately 156,176 people in the United States died from lung
cancer [54]. Cigarette smoking or the use of other tobacco products is the main cause of lung
cancer development in the general population and also in HIV-1–infected patients. Other
risk factors for lung cancer among HIV-1–infected patients include immunosuppression,
intravenous drug use, the presence of opportunistic lung infections and aging [2]. HIV-1–
infected patients exhibit a twofold increased risk of developing lung cancer relative to the
general population [3]. Importantly, it has been reported that HIV-1 infection increases the
risk of lung cancer development, even in the absence of smoking [55, 56]. The non-small cell
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lung cancer types account for 80% of the cases of lung cancer in HIV-1–infected patients. In
the United States, squamous cell carcinoma, adenocarcinoma and small cell carcinoma col-
lectively account for the most frequent NADC among HIV-1–infected people, preferentially
affecting males over females [3].
The clinical presentations of lung cancer in HIV-1–infected patients pre- and post-ART appear
to be the same. Lung cancer appears at a younger age (38–49 years) in HIV-1–infected patients
as compared to uninfected individuals (68 years) [57, 58]. There are conflicting reports, how-
ever, regarding the clinical outcomes of lung cancer in HIV-1–infected versus uninfected sub-
jects. Some studies have shown that the cancer presents more aggressively, with more severe
clinical disease course and a shorter overall survival rate in HIV-1–infected patients relative to
uninfected individuals [2].
2.3.2. Colorectal cancer
Colorectal cancer is the third most frequently occurring cancer among men and women and
the second leading cause of cancer-associated deaths in the United States [59]. The incidence of
colorectal cancer among HIV-1–infected patients has been increasing since the introduction of
ART [60]. A study conducted by Patel et al. demonstrated that the incidence rate of colorectal
cancer among HIV-1–infected individuals from 1992 to 1995 and from 1996 to 1999 was 39.9
and 39.7 per 100,000 person years, respectively. However, this number increased to 66.2 per
100,000 person years from 2000 to 2003. In contrast, the incidence rate of colorectal cancer
among the general population was 20.4, 20.5 and 21.2 per 100,000 person years for the same
three time frames [60].
A case controlled study of HIV-1–infected patients with colorectal cancer diagnosed from 1994
to 2003 revealed that this malignancy occurred at a younger age in the HIV-1–infected group
compared to the general population in the absence of HIV-1 infection [61]. Furthermore, at the
time of diagnosis, 90% of the HIV-1–infected patients presented with advanced stage cancer
(stage III/IV) compared to 57% in the uninfected group [61]. These observations were con-
firmed by Berretta et al. who reported differences in the clinical outcome between 27 HIV-1–
infected patients and 54 patients with colorectal cancer in the absence of HIV-1 infection
studied from 1985 to 2003. This malignancy presented more aggressively in the HIV-1–infected
group, as indicated by more advanced disease staging at the time of diagnosis and a shorter
survival time as compared to the uninfected patient cohort [44].
The highest incidence of colorectal cancer in the United States is found in African Americans.
Even though African Americans represent only 12% of the total population in the United
States, these individuals comprise 50% of HIV-1–infected people in this country. Colorectal
cancer develops in HIV-1–infected African American at an earlier age compared to the general
population. Kumar et al. studied the clinical presentations of colorectal cancer in a retrospec-
tive study of 17 HIV-1–infected African Americans and 42 uninfected matched controls. The
mean age of colorectal cancer diagnosis in the HIV-1–infected population was 50.70 versus
59.42 years in the control group [62]. Furthermore, 29.4% of the HIV-1–infected patients in this
study were diagnosed with colorectal cancer at a younger age (<45 years) versus 6.35% for the
control group. At the time of diagnosis, 52.94% of the HIV-1–infected patients and 43.84% of
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the uninfected controls had already presented with advanced stage colorectal cancer. Interest-
ingly, the survival time was similar for both groups in this study [62].
2.3.3. Prostate cancer
Prostate cancer is the second most frequently occurring cancer in men in the United States [63]
and will likely affect 6% of these individuals at an age of 60 within the next decade [64]. There
are conflicting data, however, regarding the incidence of prostate cancer in the HIV-1–infected
patient population. In a retrospective, multi-institutional study of HIV-1–infected patients
conducted in the United States from 1996 to 2006, Pantanowitz et al. showed that the mean
age for prostate cancer diagnosis in their cohort was 59 years. Additionally, more than half of
the patients already presented stage II–IV prostate cancer, with a mean of CD4+ T-cell count of
336 cells/μl and HIV-1 viral load of 17,319 copies/ml. The majority of these patients became
long-term survivors after hormonal treatment, radiation and/or prostatectomy [65]. In terms of
risk groups, African American men are particularly susceptible to developing prostate cancer.
Furthermore, in the setting of HIV-1 infection, it has been reported that prostate cancer might
present more aggressive in African American men [66, 67]. A retrospective study of 54 HIV-1–
infected males and 1496 uninfected patients with prostate cancer from 2000 to 2011 was
conducted to study the clinical presentation and outcome of the cancer between the two
groups. In this study, 92% of the HIV-1–infected patients were African American. At the time
of cancer diagnosis, 82% of the HIV-1–infected patients were taking ART and the remaining
14% initiated ART after cancer diagnosis. The median age was 60.7 years for the HIV-1–
infected patients and 64 years for the general population. In the HIV-1–infected group, the
median CD4+ T-cell levels were 391 cells/μl and the viral titers in 76% of these patients were
≤400 copies/ml. At the time of cancer diagnosis, 73 and 14% of the uninfected group presented
with cancer stage I/II and stage III/IV, respectively, whereas 63 and 36% of the HIV-1–infected
patient group were categorized as stage I/II and III/IV, respectively. Furthermore, HIV-1 infec-
tion was associated with a greater likelihood of presenting with advanced stage cancer at the
time of diagnosis as well as greater mortality overall [68].
3. Trends in HIV-1–associated cancers
3.1. Incidence and epidemiology
Prior to the advent of ART, KS and NHL accounted for 99% of all ACDs [69]. Following the
introduction of this therapy, however, there was an 84 and 54% decrease in the number of KS
and NHL cases, respectively. During this same time period, a 70% reduction in the incidence of
all ADCs was observed [25, 69]. Despite this dramatic decline, from 1991–1995 to 2001–2005
when ART was introduced, ADCs continue to be a major problem. For example, more than
2000 cases of ADCs were diagnosed annually in the United States between 2001 and 2005,
these cancers were more recently attributed to 15–19% of all deaths in HIV/AIDS patients [70,
71]. As previously stated, one of the most important risk factors for KS and NHL is suppres-
sion of the immune system as determined by CD4+ T-cell decline [72–74]. A low CD4+ T-cell
count (<50 cells/μl) remains a risk for developing KS, even for HIV-1–infected patients who
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receive ART [75]. Additional risk factors include advanced age and immune reconstitution
inflammatory syndrome resulting from restored immunity to specific infectious or
noninfectious antigens following the initiation of ART [76].
In contrast, the frequency of NADCs such as melanoma, HL, anal, prostate and colorectal
cancers has been steadily increasing over the past two decades [60]. The overall risk for all
NDACs in HIV-1–infected persons is approximately twofold higher than in the general popu-
lation of the same sex and age [77]. It is estimated that NADCs are currently responsible for
28% of deaths in the HIV-1–infected patient population [12]. Indeed, the frequency of NADCs
now exceeds the number of AIDS-defining cancers [78]. Using regression analysis, Coghill
et al. established an association between HIV-1 infection and cancer-related mortality of cases
reported in six states in the United States from 1996 to 2010. This study included 1,816,461
patients with cancer of whom 6459 were infected with HIV-1 and demonstrated an increased
incidence and specific mortality particularly for colorectal, lung and other NDACs [64]. Co-
infections with oncogenic viruses account for the largest number of NDACs in HIV-1–infected
individuals, but NDACs with a nonviral etiology (e.g., lung cancer) also play an important
role. The growing proportion of aged HIV-1–infected individuals, co-infections, immune defi-
cits not controlled by ART and/or risky lifestyle factors place HIV-1–infected subjects at higher
risk for developing NDACs compared to the general population [23, 79, 80].
3.2. Risk factors (examples include age, chronic inflammation, immunosuppression,
smoking, alcohol use, long-term ART)
HIV-1–infected individuals are exposed to a number of cancer risk factors, including smoking,
older age, immunosuppression, viremia and long-term ART (Figure 1). It is estimated that in
the United States, 50% of HIV-1–infected individuals smoke cigarettes, a 2.5-fold higher prev-
alence than in the general population [81]. A study conducted by Krishnan et al. identified the
risk factors for developing NADCs in a cohort of 3158 treatment-naive HIV-1–infected indi-
viduals in the United States who started ART at the initiation of the study. The results indi-
cated that smoking and CD4+ T-cell counts (<350 cells/μl) at study entry were associated with
increased risk of developing a NADCs. Anal cancer, basal cell carcinoma, HL and lung cancer
were the most common cancers reported in this study [78]. The influence of smoking on cancer
development among HIV-1–infected individuals was studied in a Danish cohort of 3503 HIV-
1–infected patients and 19,979 matched control subjects. The majority of HIV-1–infeccted
patients (77%) had been on ART for a median of 3.3 years at study entry and their median
baseline CD4+ T-cell counts were 450 cells/μl. In the HIV-1–infected group, 67% and 76% of
patients reported never or actively smoking, respectively, compared to 53% and 39% in the
uninfected group. Smoking and virus-associated cancers were most prevalent among HIV-1–
infected patients. Indeed, there was a higher risk of developing these types of cancers in the
HIV-1–infected group compared to the control population [82]. Furthermore, a recent study
showed that HIV-1–infected homosexual male smokers were at higher risk of developing HPV-
related anal cancer compared to the nonsmoker control group. Smoking was also associated
with higher HPV DNA levels, the development of high-grade anal intraepithelial lesions and
anal dysplasia [83].
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It has been suggested that the increased number of NADCs in the ART era is due in part to the
increased life expectancy following the introduction of this therapy to the HIV-1–infected
patient population [12]. A systematic review conducted by Oliveira et al. evaluated the role of
ART on the frequency of NADCs among people living with HIV-1. In this study, 21 reports
were reviewed, analyzing a total of 2 million person-years and 10,891 new cases of NADCs.
The results show that after the introduction of ART, the rate of KS and NHL decreased,
whereas the rate of cervical cancer increased. The risk of developing NADCs increased,
particularly anal, colorectal, HL, liver, lung and prostate cancers [12].
The role of immunosuppression and viremia in the development of NADCs was evaluated in a
cohort of 11,459 HIV-1–infected patients on ART in the Netherlands. Of the total number of
patients, 236 patients were diagnosed with NADCs, 102 were infection-related and 134 were
not associated with infection. The most common cancer in the infection-related group was anal
cancer (37 patients), followed by laryngeal cancer (21) and HCC (16). At the time of cancer
Figure 1. Risk factors for developing cancer in the setting of HIV-1 infection. Factors that may increase the likelihood of
developing cancer in HIV-1–infected individuals include alcohol consumption, smoking, the duration of ART, a chronic
immunoinflammatory state, CD4 count and/or advanced age. The complex interactions between ART use, HIV-1 replica-
tion, aging and other risk factors that are dynamic over time may influence tumor biology in patients with HIV-1
infection.
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diagnosis, the median CD4+ T-cell count was 340 cells/μl (range: 210–540 cells/μl). Further-
more, the longer that a patient spent with a low CD4+ T-cell count (<200 cells/μl), their
likelihood of developing an NADC, particularly with infectious etiology increased. Additional
risk factors for the development of NADCs in this patient cohort included longevity and
developing AIDS before the initiation of ART [84].
A study conducted in Portugal with HIV-1–infected patients showed that the most prevalent
NADCs in this group were skin and lung cancers and HCC. KS (32%), NHL (16%) and cervical
cancer (4%) accounted for the cases involving ADCs. Importantly, factors such as a longer
interval of HIV-1 infection and ART, as well as high CD4+ T-cell counts and HIV type 2 (HIV-2)
infection were linked to developing NADCs, whereas impaired immunity, HBV co-infection,
cigarette smoking and alcohol consumption were associated with the emergence of ADCs [85].
In a randomized clinical trial of 5472 HIV-1–infected patients, Silverberg et al. studied the
effects of discontinuing ART on cancer development. There were two groups of patients
studied based on treatment status as continuous ART and discontinuous ART. In the discon-
tinuous ART arm, the treatment was interrupted when the CD4+ T-cell counts were >350 cells/
μl and resumed when the counts were <250 cells/μl. Of the total number of patients, 70
developed cancer. There was an increased rate of KS and NHL in the discontinuous ART
group, with low CD4+ T-cell counts and the detection of HIV-1 RNA defined as risk factors.
According to these variables, the risk of developing NADCs was similar in both groups [86].
The effects of long-term use of ART on cancer development were evaluated in a cohort of
12,872 HIV-1–infected patients who were followed from 1996 to 2008. The incidence of ADC,
particularly KS and NHL, decreased as the time on ART increased. This trend was partially
attributed to the effects of ART in decreasing HIV-1 RNA levels and restoring CD4+ T cell
counts. Interestingly, there was no association between the use of ART and the risk of develop-
ing NADCs. However, there was a lower incidence of noninfectious-related NADCs as the
ART intervals were increased over time, particularly in the case of prostate cancer [87].
Increased plasma levels of interleukin (IL)-6 and C-reactive protein (CRP), two markers of
inflammation, are closely associated with cancer induction. In a prospective study of a cohort of
5023 HIV-1–infected patients, Borges et al. examined the link between the presence of inflamma-
tory factors (IL-6 and CRP) and coagulation markers (e.g., D-dimer) and cancer risk. After a
follow up of 24,000 person-years, 172 patients were diagnosed with cancer. The most frequent
infection-related malignancies were NHL, HL and anal cancer; the malignancies most often
encountered and unrelated to infection were lung, prostate and colorectal cancer. Importantly,
there was a significant association between elevated serum levels of IL-6, CR and D-dimer and
the risk of cancer development, with high levels of IL-6 exhibiting the strongest correlation [88].
4. Mechanisms of HIV-1–associated cancer
Although an unequivocal link exists between HIV-1 infection and the development of certain
cancers, it remains unclear whether HIV-1 acts directly as an oncogenic agent. In the context of
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HIV-1 infection, viral-induced tumorigenesis appears to rely on multiple factors, which typi-
cally involve cooperation between co-infecting viruses as well as aberrations in immune and
nonimmune microenvironments. In this regard, we will describe the mechanisms underlying
HIV-1–associated oncogenesis with a focus on both the direct tumor-promoting capacities of
viral products on cells and indirect causes of the cooperative induction of cancer that are
instead related to the ability of HIV-1 disease to cause profound immune dysregulation.
Notably, the importance of viral co-factor cooperation in malignant transformation is
underscored in HIV-1–infected individuals due to a high degree of immunodeficiency and/or
the chronic immune activation/inflammatory state that increases susceptibility to infection and
numerous replicative and oncogenic pathways with multiple tumor viruses [89].
The increased incidence of aggressive B-cell lymphomas in HIV-1–infected subjects compared
to individuals with other forms of immune suppression has been documented [90, 91], but
remains poorly understood. While this phenomenon may be attributed to the failure of
immune surveillance due to direct and bystander T-cell depletion and/or microenvironment
changes that define pathogenic HIV-1 infections, it stands to reason that HIV-1 replication
products may also contribute to oncogenesis. In further support of this idea, it has been shown
that HPV-induced cervical dysplasia and cancer are frequent complications of HIV-1 infection
[92–94], with no clear association between occurrence and the degree of host immune suppres-
sion [93, 95]. Thus, while this malignancy has been shown to be aggressive, less responsive to
treatment and often recurrent in HIV-1–infected women, there appears to be no difference in
the severity of neoplasia in asymptomatic patients with HIV-1 infection compared to those
who have progressed to AIDS [95]. These collective clinical observations indicate that immu-
nodeficiency may not be the sole mediator of cancer development during the course of HIV-1
disease and implicate a more direct role for HIV-1 with respect to potentiating neoplasia.
The contributions of HIV-1–induced molecular alterations in inducing neoplastic transforma-
tion independently of immune system perturbation have been demonstrated, primarily
through the use of in vitro cell line models. In the context of KS, a direct cooperative role of
HIV-1 in mediating tumorigenesis has been observed. In a cell line model derived from a
primary effusion lymphoma (PEL), HIV-1 infection triggers reactivation of Kaposi’s sarcoma
herpesvirus (KSHV) or HHV-8 and this effect was the direct action of the HIV-1 transactivator
protein Tat [96]. Tat has been shown to be released from HIV-1–infected cells and may bind to
and enter uninfected cells, including endothelial cells through its protein transduction domain
[97–99]. Tat-mediated signaling has been shown to promote endothelial cell migration and
matrix invasion in vitro as well as angiogenesis in vivo [100–103]. In addition, human KS cells
grow more aggressively in HIV-1 Tat transgenic CD4+ T-cell depleted mice compared to
nontransgenic control animals [104], although the direct role of Tat in KS development remains
controversial [105]. Furthermore, when HIV-1 and KSHV genomes are present in the same
cellular environment, bilateral positive transcription of genes from both viruses has been
observed. Notably, HIV-1 Tat and Vpr independently activate KSHV transcription, whereas
the KSHV KIE2 protein induces activation of HIV-1 LTR-driven transcription [106]. Finally, it
has been suggested that by regulating a number of cellular targets, HIV-1 Tat may be involved
in altering DNA repair in host cells, potentially leading to genomic instability which may give
rise to mutations and contribute to oncogenesis [107]. In particular, Tat induces expression of
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the DNA polymerase beta gene, which codes for a central mediator in the DNA base-excision
repair pathway [108]; HIV-1 Tat has also been implicated in playing a direct role in double-
strand break DNA repair, as cellular extracts containing Tat possess a reduced capacity to re-
join linearized DNA [109]. These observations may explain at least in part why HIV-1 and
KSHV co-infected individuals possess a higher risk for developing KS.
As mentioned earlier in this review, similar to KS, NHL in AIDS patients is associated with
another co-infecting virus, in this case, EBV. While current evidence suggests that the
chronic immunoinflammatory state associated with HIV-1 disease contributes to B cell
activation and ultimately to lymphomagenesis, HIV-1 replication products may also directly
contribute to lymphoma induction. HIV-1 envelope protein gp120 has the ability to directly
activate B cells through its interaction with DC-SIGN, leading to immunoglobulin gene
class-switch recombination, interleukin secretion and activation-induced cytidine deaminase
(AID) expression [110]. Because the HIV-1 envelope interfaces with a number of cellular
proteins with diverse functions including adhesion molecules, major histocompatibility
complex (MHC) components as well as macrophage, B- and T-cell surface proteins, it would
be interesting to determine which of these constituents contribute(s) to B-cell activation and
consequential lymphomagenesis [111]. It has also been demonstrated that Tat alters the
proliferative capacity and apoptosis sensitivity of EBV-immortalized cell lines, suggesting
that cells expressing Tat may have a selective growth advantage, thereby potentially giving
rise to clones with enhanced oncogenicity [112]. An interaction between HIV-1 Tat and the
pRb2/p130 oncosuppressor protein has also been observed, but the effects of Tat on the cell
cycle are conflicting, which may be attributed to its dose- as well as cell type-dependent
activities [113–115].
Viral cooperativity in the potentiation of cancer induction may involve more than two agents. In
fact, one of the most relevant examples of this type of viral cooperation exists between HIV-1,
EBV and KSHV in promoting the development of PEL, a prototypic lymphoma that arises in
EBV and KSHV co-infected tumor cells in HIV-1–infected patients [116]. Reciprocal molecular
interactions between EBV and KSHV promote each other latency in PEL cells, which may
contribute to the establishment and maintenance of tumors [117]. Because HIV-1 can induce
KSHV transcription (i.e., through Tat and Vpu) and EBV as well as KSHV replication products
(EBNA-2 [118] and ORF45 [119], respectively) activate the HIV-1 LTR, viral cooperation appears
to be a potential mechanism underlying lymphomagenesis in this setting.
As previously indicated, the occurrence of HPV-induced cervical cancer is independent of
immune suppression, unlike a number of other AIDS-associated neoplasms. However, the
molecular underpinnings of a more aggressive malignancy in HIV-1–infected women with
cervical cancer are poorly understood. In this regard, HIV-1 Tat has been shown to increase
the expression of HPV E6 and E7 oncoproteins [120, 121]; the E6-p53 interaction and E7-Rb
complex formation result in functional inactivation and aberrant cell cycle control, which is a
critical regulator of HPV-induced cervical carcinogenesis [122]. Rb and its family members
such as pRb2/p130 may be affected by HIV-1 expression; HIV-1 Tat may block pRb2/p130
mRNA expression, but it is unclear whether or not Tat changes the architecture of the pRb2/
p130-E7 interaction [123]. Furthermore, HIV-1 Tat expression has been shown to decrease the
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mRNA levels of cyclin-dependent kinase inhibitors p21 and p17 [123] that have been impli-
cated in the control of the G0/G1 transition and are inactivated by the HPV E7 protein [124,
125]. However, the end result in cervical carcinogenesis and disease progression of these Tat-
induced oncogene and tumor suppressor changes remains unclear.
The tumor microenvironment includes a number of immune cellular components, including
activated T cells, B cells and macrophages. Over the past several years, the importance of HIV-1
interactions within the microenvironment has gained increasing recognition. HIV-1 disease
results in a profound perturbation of cytokine/chemokine levels, which facilitates the develop-
ment of antiviral immunity as previously reviewed [126]. However, these mediators can also
have a detrimental effect on the host by limiting the development of potent immune responses
elicited against infection [127] and directly or indirectly affecting cancer development. In fact,
studies of cytokines in HIV-1–infected patients were among the earliest reports of aberrant
cytokine levels being associated with lymphoma risk [128, 129]. Elevated levels of IL-6, IL-10,
CXCL13 and TNFα are associated with increased risk for the development of NHL in HIV-1–
infected individuals [128–131]. The induction of pro-inflammatory mediators by HIV-1 infec-
tion likely alters the elaboration of other immunomodulatory factors, thus influencing cellular
proliferation, apoptosis sensitivity and other physiologic functions associated with the micro-
environment [89].
HIV-1–dependent skewing from T helper (h)1 to Th2 CD4+ T-cell subpopulations has been
considered an important step in immune dysregulation as previously reviewed [132].
Increased Th2 differentiation likely precedes the development of AIDS-related NHL and may
also play a role in Th17 upregulation [111]. Th17 cells are present in the microenvironment of a
number of different murine and human tumors [133]. Furthermore, in the context of AIDS-
NHL pathogenesis, Th2 or Th17 cytokines are known to drive AID expression [134].
The dysregulation of cytokine/chemokine pathways in the HIV-1–infected patient may also
promote neoangiogenesis. In addition to the aforementioned role of Tat in stimulating capil-
lary formation [135], the HIV-1 matrix protein, p17, has been shown to promote angiogenesis
through a different mechanism involving the ligation of chemokine receptors [136]. More
specifically, the release of p17 from HIV-1–infected cells binds to CXCR1, which subsequently
drives human monocytes into the microenvironment in an IL-8 chemokine-like manner
resulting in sustained inflammation [137]. Increased levels of IL-6 and TNFα in the plasma of
HIV-1–infected patients can induce COX-2 and PGE2 synthesis, which have been linked to the
development of AIDS-related cervical cancer [138], an effect that could be related to the
promotion of angiogenesis [139, 140]. The precise role of HIV-1–driven angiogenic mecha-
nisms in the development and progression of cancer has not been elucidated and warrants
further investigation.
Finally, the nonimmune microenvironment may drive the development and/or progression of
AIDS-related cancers and this may also involve mechanisms of viral cooperation [89]. In
lymphomas, the nonimmune microenvironment is largely composed of endothelia, stromal
cells and fibroblasts that contribute to tumorigenicity. In AIDS-associated NHLs, studies on
nonimmune microenvironmental components have focused on neoangiogenesis, although it is
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presently debated whether HIV-1 may influence this process through productive infection of
endothelial cells [89]. Interestingly, Liapis et al. recently demonstrated that the amount of
neovasculature was consistently increased in AIDS-NHL compared to sporadic NHLs. In these
patients, AIDS-NHL microvessel density in virus-infected tissue was directly correlated with
EBV expression [135]. While neovascular abnormality may be considered a common process
observed in a number of viral diseases, the identification of biomarkers in nonimmune micro-
environments and the precise mechanisms of viral oncogenesis in these settings may prove to
be important in the diagnosis and management of HIV-1–associated lymphomas.
The mechanistic underpinnings of HIV-1 co-infection in accelerating the progression of HCC
by HCV may be related to direct effects of HIV-1 on activated hepatic stellate cells (HSCs), the
Figure 2. Mechanisms of HIV-1–associated cancer. Increased oncogenesis in the setting of HIV-1 disease usually involves
co-infection with other viruses and immune dysfunction, accompanied by decreased immune surveillance. Persistent
immune activation as a consequence of HIV-1 infection may lead to chronic tissue damage and the formation of infection-
induced microenvironments that potentiate cancer induction. HIV-1 and its products may also influence oncogenesis
(usually in the context of viral cooperativity) independently of immune suppression through cell cycle deregulation and/
or influencing the nonimmune microenvironment (e.g., increased extracellular matrix, pro-fibrogenic factors and blood
vessel formation).
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primary fibrogenic cell type in the liver. HSCs are permissive for HIV-1 infection, support viral
gene expression and are capable of transmitting infectious virus [141]. Other than induction of
pro-inflammatory cytokines, productive infection of HSCs promotes fibrogenic collagen I
expression [141]. Similarly, exposing hepatocytes to HIV-1 results in increased production of
reactive oxygen species (ROS), collagen and tissue inhibitor of metalloproteinase 1 (TIMP1), an
effect that is amplified by concurrent HCV exposure [142]. Another proposed way by which
HIV-1 promotes fibrosis is through induction of apoptosis in response to envelope proteins
[143, 144] and/or expression of tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) and its cognate death receptors DR4 and DR5 [145, 146]. Taken together, an increase
in fibrous tissue with the concomitant destruction of liver cells provides the “soil” for devel-
opment of cancerous nodules following long periods of chronic liver diseases [147–149]. In
addition to highly profibrotic proteins and extracellular matrix constituents, characterization
of other nonimmune microenvironment components in the context of HIV-1 infection as well
as co-infection conditions is required for the elucidation of well-defined pathophysiological
pathways to inform mechanism-based approaches directed against HIV/AIDS-related tumors.
Mechanisms of HIV-1–associated oncogenesis and cancer progression are summarized in
Figure 2.
5. Management of cancer in HIV-1–infected patients
HIV-1–infected individuals with cancer have lower rates of survival relative to individuals not
infected with HIV-1 [150]. While this may be attributed to the aggressive nature of malignancies
in the setting of HIV-1–driven immune dysfunction, alternative explanations include the
decreased efficacy or increased toxicity of cancer therapy [150–152]. In addition, the disparity
between HIV-1–infected and uninfected patients following cancer diagnosis could potentially
be a consequence of inadequate cancer treatment due to a survival decrement [153]. Indeed,
many HIV-1–infected patients are excluded from clinical trials of cancer therapies and this may
contribute to the lack of evidence-based strategies for the management of these patients,
especially if treatments are perceived to have diminished effectiveness and/or enhanced toxic-
ity in the background of HIV-1 infection [154].
The absence of cancer treatment for HIV-1–infected participants in a recent study with colon
cancer, DLBCL and non-small-cell lung cancer further underscores treatment disparities and
raises concern, particularly considering the curative potential of therapy for early-stage
cancer [154]. Reduced treatment rates of cancer in the HIV-1–infected population may also
be attributed to the limited experience of healthcare providers in managing these cases. Ideal
cancer therapy regimens for individuals on ART remain unknown due to a lack of published
data to guide clinical decision-making. Furthermore, treatment can be challenging because
of drug interactions between antineoplastic agents and antiretrovirals as well as increased
immunosuppression from chemotherapy and/or radiation [155, 156]. Notably, some chemo-
therapeutic agents and ART drugs are metabolized by a similar cytochrome p450 enzyme
pathway, which could influence the clearance of these agents and affect toxicity as well as
efficacy [157]. Thus, when the concurrent use of ARTand radio/chemotherapy is anticipated,
Human Immunodeficiency Virus (HIV) Infection and Cancer
http://dx.doi.org/10.5772/67162
19
overlap in toxicity and drug-drug interactions may influence the optimal choice of cancer
treatments [158].
In some cancers, such as DLBCL and anal cancer, results are available to inform the treatment of
HIV-1–infected patients [159–163]. Prior to the introduction of ART, low-dose and risk-adapted
intensive chemotherapeutic regimens as well as infusional chemotherapy were evaluated for
HIV-1–associated NHLs [164, 165]. Outcomes were poor regardless of the type of therapy used
and were accompanied by substantial toxicity and the occurrence of opportunistic infections
[166–172]. However, since the introduction of ART, a paradigm shift has taken place in the
treatment of HIV-1–infected lymphoma patients with survival approaching that of HIV-1–
negative subjects [116, 165, 172, 173]. Immunotherapy with anti-CD20 monoclonal antibody
(rituximab) and/or standard full-dose chemotherapy can now be safely administered to HIV-
1–infected patients in the presence of ARTwith supportive care including hematopoietic growth
factors and prophylaxis for opportunistic infections [173–177]. High-dose chemotherapy and
peripheral autologous stem-cell transplantation (ASCT) can be used as salvage therapy in patients
with HIV-1 who present with relapsed and refractory lymphoma, including HL [178–183].
Some lymphomas in the setting of HIV-1 infection require special considerations when
selecting the most appropriate cancer treatment plan. For example, HIV-1–associated Burkitt
lymphoma remains controversial, with the CHOP (cyclophosphamide, doxorubicin, vincris-
tine and prednisone) regimen not currently recommended [175, 184, 185]. The results of small
retrospective and phase II clinical trials suggest that intensive chemotherapy for ART-treated
Burkitt lymphoma patients with HIV-1 may be acceptable [184, 186, 187].
For other cancers, HIV-1–infected individuals have been largely excluded from clinical trials
because they are considered to be vulnerable patients and, therefore, randomized data related
to treatment outcomes are unavailable [188]. Nevertheless, case reports and retrospective
studies conducted after the introduction of ART have suggested similar treatment toxicity
with standard therapy [38, 57, 154, 189–193]. For example, cervical cancer is very common in
HIV-1–infected women with an aggressive course and poor treatment outcome [194, 195].
Treatment options for cervical cancer include surgery, radiotherapy and chemotherapy either
alone or in combination. In regions with a high prevalence of cervical cancer, the majority of
patients receive chemoradiotherapy, which can impair immunity [196]. A number of different
therapeutic modalities and modifications have been used to improve outcome of treatment in
HIV-1–infected patients with cervical cancer. However, there are no standard guidelines for the
management of HIV-1–infected patients diagnosed with cervical cancer and the outcome of
standard therapy remains poor. A recent systematic review of cervical cancer management in
HIV-1–infected individuals along with their treatment outcomes [197] revealed that patients
who started ART early exhibited higher rates of completion of their cancer treatment protocol,
suggesting that ART should be commenced early after cervical cancer diagnosis to ensure less
toxicity and better compliance with therapy [198–201]. Thus, as it currently stands, HIV-1–
infected cervical cancer patients should be managed like their uninfected counterparts [197].
Similarly, recommended treatment options for prostate cancer in HIV-1–infected men are the
same as those individuals without HIV-1 infection [191]. Some patients may choose to defer
therapy for an extended period of monitoring known as active surveillance. In the ART era,
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prostate-specific antigen (PSA) kinetics and prostate cancer behavior do not seem to differ
between HIV-1–infected and uninfected subjects [191, 202]. Thus, although long-term treat-
ment outcomes in HIV-1–infected patients remain uncertain, these individuals should be
offered all screening and treatment options as men in the general population [202].
ART is a main component of treatment for all patients with KS and is an effective anti-KS
therapy for approximately 60–70% of patients with limited cutaneous lesions [203–205]. In
cases of advanced stage visceral KS or aggressive disease, systemic chemotherapy should be
combined with ART. First-line chemotherapy includes combination regimens or pegylated
liposomal (L) doxorubicin, which has been shown to be better tolerated [205–207] (with an
objective response rate of 59–82%). Second-line chemotherapy consists of low-dose paclitaxel
for patients who are resistant to anthracyclines (with an objective response rate of 60–70%)
[208]. The emergence of immune reconstitution inflammatory syndrome in ART-treated HIV-
1-infected patients, which may lead to the development of KS or accelerate its progression,
undoubtedly poses a major challenge to current disease management options [209, 210].
In the era of ART, HIV-1–infected patients with cancer can be treated with more aggressive
regimens, including intensive chemotherapy with concomitant stem cell transplants in the case
of hematologic malignancies and/or combined chemotherapeutic protocols [116]. Due to the
potential risk of adverse drug-drug interactions, the simultaneous use of antineoplastic drugs
with antiretroviral agents has been debated [53, 156, 211]. However, contemporary guidelines
support the use of ART during chemotherapy [173, 212]. With regard to the management of
most HIV-1–associated cancers, treatments that achieve the highest rates of progression-free
survival in uninfected individuals are becoming increasingly applicable to HIV-1–infected
patients [116]. Nevertheless, additional prospective studies are urgently required to define
toxicities associated with the concurrent use of ART and chemotherapy. Such reports should
be instrumental in developing evidence-based treatment criteria for these patients [158]. Until
this is achieved, healthcare providers should individualize cancer treatment plans (e.g., che-
motherapy, surgery, radiation therapy) for HIV-1–infected patients based on laboratory results,
the presence of renal or liver dysfunction and the risk of potential drug-related toxicities.
6. Conclusions
Although the management of HIV-1 infection has improved considerably in the last few
decades, HIV-1–infected patients are still at high risk compared to the general population,
with respect to the development of a spectrum of life-threatening malignancies. There are a
number of cancers that present in HIV-1–infected patients at a younger age, more aggressively
and with a shorter survival time than a comparable uninfected population. This implies that
despite the partial restoration of the immune system in HIV-1–infected patients due to effica-
cious ART protocols, HIV-1 infection has been identified as a risk factor for the development of
cancer, particularly NADCs. Indeed, the oncogenic potential of Tat and gp120 has been exam-
ined in various cell lines as well as the cooperation between these proteins with co-infecting
viruses to enhance cell transformation. A better understanding of the interactions between
HIV-1 and a number of oncogenic viruses in conjunction with immune and nonimmune cells
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may lead to the development of better therapeutic approaches for the management of cancer in
HIV-1–infected patients. Furthermore, there are few randomized studies that have addressed
the management of cancer in HIV-1–infected patients. Some of the challenges in the treatment
of cancer in HIV-1 infection include increased immunosuppression induced by chemotherapy
and/or radiation, as well as the potential for synergistic toxicity caused by antiretrovirals and
antioncogenic treatments. Thus, it is imperative that HIV-1–infected patients are included in
studies to determine the proper therapeutic approaches that these patients need when diag-
nosed with cancer.
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